Intravitreal @entity15127 for the treatment of @entity63 XXXX .

@entity1 @entity15127 @entity63 @entity1103 @entity941
PURPOSE: @entity15127 has been shown to be effective in treating @entity1103 ( @entity1103 ). In the original Phase II/III trial, however, @entity1 with @entity63 were excluded. In this study, we treated @entity1 with @entity63 @entity1103 . METHODS: @entity63 was defined as a 30% increase in the area of the foveal avascular zone (FAZ) at 45 seconds on fundus @entity941 angiography. In addition, the @entity1 had diffuse foveal-involving @entity1103 with a central subfield thickness (CST) of >300  m on spectral-domain optical coherence tomography. Five intravitreal @entity15127 injections were given 6 weeks apart. The final study visit was 6 weeks after the fifth injection. The primary outcome was change in the size of FAZ. Secondary outcomes were change in best-corrected visual acuity (BCVA) and the change in CST. RESULTS: Thirty @entity1 were enrolled. Three were unable to complete the full course of treatment. Their outcomes were carried forward for the first part of this analysis. There was no statistically significant change in the mean size of the FAZ from baseline to the final visit. Subclassifying @entity1 as those with minimal/moderate @entity63 (16 @entity1 , FAZ area <1,000 pixels) and those with more severe @entity63 (14 @entity1 , FAZ area >1,000 pixels) also showed no statistically significant change in the mean area of the FAZ. On average, BCVA increased and CST decreased from baseline to the final visit, but these changes were not statistically significant. Using per protocol analysis on those @entity1 who completed the full course of treatment, the mean BCVA increased from 49.2 to 53.9 letters (P=0.046). CONCLUSION: In this study, intravitreal injection of @entity15127 did not significantly alter the size of the FAZ in @entity1 with varying degrees of @entity63 @entity1103 . There was, however, a significant improvement in mean BCVA in those who completed the treatment course.
